Amundi Royalty Pharma PLC Call Options Transaction History
Amundi
- $264 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RPRX
# of Institutions
412Shares Held
283MCall Options Held
578KPut Options Held
47.5K-
Morgan Stanley New York, NY41.1MShares$1.09 Billion0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA37.6MShares$993 Million0.02% of portfolio
-
Black Rock Inc. New York, NY23MShares$608 Million0.01% of portfolio
-
Baillie Gifford & CO16.1MShares$426 Million0.35% of portfolio
-
Viking Global Investors LP12.1MShares$320 Million1.32% of portfolio
About Royalty Pharma plc
- Ticker RPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 437,139,008
- Market Cap $11.6B
- Description
- Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...